drugset / Trial / NCT01946789
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer
Timeline
- Start
- 2014-05
- Primary completion
- 2017-08
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | N-803 | Protein / enzyme biologic | 0.3 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 0.5 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 1 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 3 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 6 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 15 ug/kg | Intravenous |
| Subject | N-803 | Protein / enzyme biologic | 20 ug/kg | Intravenous |